Frontiers in Pharmacology (Oct 2022)

Pharmacological interventions on smoking cessation: A systematic review and network meta-analysis

  • Xue Shang,
  • Xue Shang,
  • Xue Shang,
  • Kangle Guo,
  • Kangle Guo,
  • Kangle Guo,
  • Fenfen E.,
  • Fenfen E.,
  • Fenfen E.,
  • Xinxin Deng,
  • Xinxin Deng,
  • Xinxin Deng,
  • Yongsheng Wang,
  • Yongsheng Wang,
  • Yongsheng Wang,
  • Ziyi Wang,
  • Ziyi Wang,
  • Ziyi Wang,
  • Yanan Wu,
  • Yanan Wu,
  • Yanan Wu,
  • Meng Xu,
  • Meng Xu,
  • Meng Xu,
  • Chaoqun Yang,
  • Chaoqun Yang,
  • Chaoqun Yang,
  • Xiuxia Li,
  • Xiuxia Li,
  • Xiuxia Li,
  • Kehu Yang,
  • Kehu Yang,
  • Kehu Yang

DOI
https://doi.org/10.3389/fphar.2022.1012433
Journal volume & issue
Vol. 13

Abstract

Read online

Objective: A network meta-analysis based on randomized controlled trials was conducted to investigate the effects of pharmacological interventions on smoking cessation.Methods: English databases were searched to obtain randomized controlled trials reporting the effect of pharmacological interventions on smoking cessation. The risk of bias for the included trials was assessed using Cochrane Handbook tool. Stata 15.1 software was used to perform network meta-analysis, and GRADE approach was used to assess the evidence credibility on the effects of different interventions on smoking cessation.Results: A total of 159 studies involving 60,285 smokers were included in the network meta-analysis. The analysis involved 15 interventions and which yielded 105 pairs of comparisons. Network meta-analysis showed that varenicline was more helpful for smoking cessation than other monotherapies, such as nicotine replacement therapy [Odds Ratio (OR) = 1.42, 95% confidence interval (CI) (1.16, 1.73)] and bupropion [OR = 1.52, 95% CI (1.22, 1.89)]. Furthermore, combined interventions were superior to monotherapy in achieving smoking cessation, such as varenicline plus bupropion over bupropion [OR = 2.00, 95% CI (1.11, 3.61)], varenicline plus nicotine replacement therapy over nicotine replacement therapy [OR = 1.84, 95% CI (1.07, 3.18)], and nicotine replacement therapy plus mecamylamine over naltrexone [OR = 6.29, 95% CI (1.59, 24.90)]. Finally, the surface under the cumulative ranking curve value indicated that nicotine replacement therapy plus mecamylamine had the greatest probability of becoming the best intervention.Conclusion: Most pharmacological interventions demonstrated a benefit in smoking cessation compared with placebo, whether monotherapy or combination therapy. Moreover, confirmed evidence suggested that some combination treatments, such as varenicline plus bupropion and nicotine replacement therapy plus mecamylamine have a higher probability of being the best smoking cessation in

Keywords